The innovation of the Controlled **Temperature** Chain (CTC) where do we go from here?

A CAN DEVELOP AND A COMPANY AN



World Health Organization Anna-Lea Kahn - WHO-HQ/ EPI 14th TechNet Conference - Bangkok, Thailand 13 May 2015

Programmatic definition of a **Controlled Temperature Chain (CTC)**

- a specific set of conditions allowing for a vaccine to be stored and transported outside of the traditional 2° to 8°C cold chain
 - One excursion, just prior to administration Ambient temperatures up to 40° or more Specifically limited duration/at least 3 days
- Current EPI priorities for CTC:
 - Campaigns & special settings
 - Appropriate tools: VVM, PTTI, Monitoring
 - Tested (for safety & stability), Licensed & Prequalified





nanization

The CTC Agenda : UPSTREAM

- Development and licensure of more CTC-compatible vaccines
 - Clarify definition and programmatic priorities
 - Regular dialogue with manufacturers and regulators
 - \checkmark Promoting awareness and interest in CTC
 - \checkmark Exploring thermostability of existing vaccines
 - Encouraging CTC consideration in new product development
 - Generic Preferred Product Profiles (VPPAG)
 - ✓ Clarifying barriers and challenges / identifying solutions
 - Development of WHO Guidelines on the Regulatory pathway for CTC licensure



CTC licensure to date

- December 2012 Meningitis A Vaccine (MenAfriVac) licensed, prequalified and pilot tested for CTC
 4 days / 40°C
- May 2015 Pneumococcal Conjugate Vaccine 13-valent (Prevnar13) licensed and prequalified for CTC, guidance to be developed
 - o 3 days / 40°C
- End of 2015 Oral Cholera vaccine (Shanchol) expected to be licensed and prequalified for CTC
- 8 manufacturers working on generating data in support of CTC for at least 10 different vaccines.




The CTC agenda: DOWNSTREAM

- Scale up country-level experience / boost demand
 Integrating CTC into MenAfriVac campaigns
 - Generating more data in support of CTC
 - ✓ Operational Research: KAP, Cost-benefits, Coverage
 - ✓ Wastage, AEFI, Monitoring tools
 - Advocating for CTC with national stakeholders
 - Ensuring appropriate technical support
 - Improving training, supervision, and monitoring tools
 - Documenting and applying lessons learned
 - Developing field implementation guidelines for new vaccines



CTC Demand/Implementation Momentum



CTC | 15 May 2015

